摘要
目的:研究骨桥蛋白(osteopontin,OPN)在乳腺癌各分子亚型中的表达及其临床意义。方法:收集2000年1月至2003年12月第二军医大学长海医院的99例乳腺癌组织标本,免疫组织化学法检测ER(estrogen receptor)、PR(progesteronereceptor)和HER-2(human epidermal growth factor receptor-2)的表达,并据此将乳腺癌患者分为luminal A型、luminal B型、HER-2过表达型和基底细胞样型。免疫组织化学法测定各分子亚型乳腺癌组织中OPN的表达情况,并分析OPN表达与乳腺癌患者临床病理特征的关系。结果:根据ER、PR和HER-2的不同表达情况,99例乳腺癌患者中luminal A型45例、luminal B型27例、HER-2过表达型14例、基底细胞样型13例。OPN在luminal A型、luminal B型、HER-2过表达型和基底细胞样型中表达率分别为22.2%、29.6%、71.4%和61.5%,HER-2过表达型和基底细胞样型乳腺癌组织中OPN表达率均高于luminal A型和luminal B型(P<0.01)。OPN低表达的乳腺癌患者生存率高于OPN高表达者,两者差异有统计学意义(P<0.01)。结论:OPN在基底细胞样型和HER-2过表达型乳腺癌组织中高表达,其表达可作为乳腺癌预后的评估指标之一。
Objective：To study the expression of osteopontin（OPN）in breast carcinoma of different molecular subtypes and its clinical significance.Methods：A total of 99 breast cancer samples were collected from patients who were treated during Jan.2000 to Dec.2003 in Changhai Hospital.Expression of ER,PR and HER-2 was detected by inmmnohistochemical staining,and the samples were categorized as follows：luminal A,luminal B,HER-2 over-expression subtype,and basal-like subtype.The expression of OPN in all molecular subtypes was detected by immunohistochemical-SP method,then the correlation of OPN expression with patients＇ clinical and pathological features was analyzed.Results：According to the expression of ER,PR and HER-2 in 99 breast cancer patients,there were 45 luminal A,27 luminal B,14 HER-2 over-expression and 13 basal-like subtypes.The positive rates of OPN in luminal A,luminal B,HER-2 over-expression and basal-like subtypes were 22.2%,29.6%,71.4% and 61.5%,respectively.The positive rates of OPN in HER-2 over-expression and basal-like subtypes were significantly higher than those in luminal A and luminal B subtypes（P〈0.01）.The survival rate of patients with low OPN expression was significantly higher than that of patients with high OPN expression（P〈0.01）.Conclusion：OPN is highly expressed in basal-like and HER-2 over-expression subtypes of breast cancer,which indicates that OPN may be a useful indicator for prognosis of breast carcinoma.
出处
《中国肿瘤生物治疗杂志》
CAS
CSCD
北大核心
2010年第4期439-443,共5页
Chinese Journal of Cancer Biotherapy
基金
国家自然科学基金资助项目(No.30870975)~~
